Table 6.
Subgroup analyses of RHR in Clinically Meaningful Subsets.
| Groups | Number of patients | Events | Crude | p for interaction | Adjusted * | p for interaction | ||
|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | p-value | HR (95%CI) | p-value | |||||
| Etiology | 0.034 | 0.005 | ||||||
| Organic TR | 686 | 51 | 1.18 (1.04–1.32) | 0.007 | 1.18 (1.03–1.35) | 0.017 | ||
| Functional TR | 1,025 | 78 | 1.08 (0.98–1.19) | 0.129 | 1.03 (0.93–1.14) | 0.574 | ||
| Other | 129 | 13 | 1.51 (1.20–1.89) | <0.001 | 1.56 (1.24–1.95) | <0.001 | ||
| NYHAc | 0.068 | 0.107 | ||||||
| NYHA < III | 1,300 | 54 | 1.15 (1.03–1.28) | 0.011 | 1.21 (1.08–1.37) | 0.001 | ||
| NYHA≥III | 548 | 111 | 1.01 (0.92–1.10) | 0.908 | 1.07 (0.98–1.17) | 0.153 | ||
| LVEF | 0.437 | 0.680 | ||||||
| LVEF <50 | 289 | 55 | 1.06 (0.94–1.18) | 0.335 | 1.09 (0.95–1.24) | 0.212 | ||
| LVEF≥50 | 1,559 | 110 | 1.12 (1.03–1.21) | 0.009 | 1.13 (1.03–1.23) | 0.011 | ||
| β-blocker | 0.018 | 0.040 | ||||||
| Yes | 967 | 96 | 1.05 (0.96;1.14) | 0.267 | 1.05 (0.95–1.16) | 0.379 | ||
| No | 1,046 | 69 | 1.26 (1.11;1.41) | <0.001 | 1.23 (1.09–1.39) | <0.001 | ||
*
Adjusted for age, atrial fibrillation, sex, BMI, diabetes, CAD, PH, eGFR, severe TR, LVEF, LVEDDi, NYHAc, and etiology when they were not the strata variables. BMI, body mass index; CAD, coronary heart disease; eGFR, estimated glomerular filtration rate; LVEDDi, indexed left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension; RHR, resting heart rate; TR, tricuspid regurgitation.